2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Sales - EUR | 187.513 | 195.098 | 204.077 | 232.395 | 252.124 | 160.109 | 152.782 | 159.321 | 184.767 | 213.292 |
Total Income - EUR | 194.370 | 195.938 | 204.489 | 237.263 | 254.359 | 411.425 | 153.014 | 159.708 | 184.790 | 213.376 |
Total Expenses - EUR | 179.996 | 190.293 | 209.657 | 229.577 | 246.643 | 196.886 | 169.988 | 169.859 | 187.653 | 207.271 |
Gross Profit/Loss - EUR | 14.374 | 5.645 | -5.169 | 7.685 | 7.716 | 214.539 | -16.974 | -10.151 | -2.864 | 6.105 |
Net Profit/Loss - EUR | 11.854 | 4.464 | -5.664 | 5.511 | 5.173 | 210.424 | -18.398 | -11.749 | -4.740 | 3.957 |
Employees | 4 | 4 | 4 | 5 | 5 | 5 | 4 | 4 | 4 | 4 |
Check the financial reports for the company - Farmako Srl
2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Fixed Assets | 5.497 | 4.904 | 4.303 | 3.926 | 3.555 | 4.940 | 4.328 | 3.821 | 3.433 | 3.025 |
Current Assets | 74.715 | 87.772 | 80.551 | 110.444 | 88.949 | 244.644 | 65.680 | 62.369 | 64.076 | 70.885 |
Inventories | 66.981 | 81.339 | 74.910 | 96.326 | 71.910 | 51.715 | 49.020 | 48.337 | 46.421 | 49.934 |
Receivables | 7.231 | 5.009 | 1.870 | 11.740 | 15.673 | 192.858 | 13.974 | 13.244 | 16.188 | 18.104 |
Cash | 503 | 1.424 | 3.771 | 2.378 | 1.366 | 71 | 2.686 | 788 | 1.468 | 2.847 |
Shareholders Funds | 27.623 | 29.639 | 16.641 | 19.566 | 24.380 | 211.404 | 10.172 | -1.802 | -6.548 | -2.571 |
Social Capital | 861 | 868 | 860 | 845 | 829 | 813 | 798 | 780 | 783 | 780 |
Debts | 52.589 | 63.037 | 68.212 | 94.943 | 68.124 | 38.180 | 59.836 | 67.992 | 74.057 | 76.480 |
Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Exchange rate - RON | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 | 4.4821 |
Main CAEN | "4773 - 4773" | |||||||||
CAEN Financial Year |
4773
|
Subscriptions Financial Reports
You can check the financial situation of the companies in relation to the industry of which it is a part, credit limits and the risk of insolvency and suspension of accounts.
Comments - Farmako Srl